How much reduced unemployment benefits could slash consumer spending and when people with COVID-19 pose the greatest risk of spreading the virus
There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. PSTV has risen $0.19 from the previous closing price of $2.68 on volume of 590,535 shares.
ET on SmarterAnalyst CLDX, AMC among premarket gainers All statements in this press release other than statements of historical fact are forward-looking statements. In the second half of Fiscal Year 2020, the Company intends to focus on a number of additional business objectives and potential milestones: * Report preliminary RNL™ data from the ReSPECT Phase I dose finding trial in recurrent glioblastoma * Finalize RNL Phase 2/pivotal trial plan in recurrent glioblastoma * Seek RNL Orphan Drug Designation decisions from regulatory agencies * Complete evaluations of additional external and internal drug development candidates * Initiate IND-enabling RNL studies for additional indications * Explore partnership opportunities for RNL, DocePLUS and DoxoPLUS assets“Following the close of our most recent in-licensing transaction, we have made steady progress in expediting the ReSPECT trial,” said Dr. Marc Hedrick, President and Chief Executive Officer of Plus Therapeutics.
Replay:http://ir.plustherapeutics.com/events/default.aspx About Plus Therapeutics, Inc.Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Currency in USD
* In Q2 2020, 162,500 series U warrants were exercised, raising $0.36M. Stock quote and company snapshot for PLUS THERAPEUTICS INC (PSTV), including profile, stock chart, recent news and events, analyst opinions, and research reports.
Over the past year the S&P 500 has risen 16.09% while PSTV has fallen -54.37%.
Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Its products include Rhenium NanoLiposome (RNL) and DocePLUS. Replay:http://ir.plustherapeutics.com/events/default.aspx About Plus Therapeutics, Inc.Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionucleotides for several cancer targets. PSTV lost -$20.76 per share in the over the last 12 months. PlusTherapeuticsInc . We believe RNL has the potential of improving brain tumor therapy and that of other difficult to treat radiosensitive tumors.”Q2 2020 Financial Highlights * Net cash used in operating activities was $2.9 million for the six months ended June 30, 2020, compared to $4.4 million during the same period in 2019. These statements include, without limitation, statements regarding the following: the design and potential of the Plus Therapeutics portfolio to reformulate, deliver and commercialize multiple novel, proprietary drugs targeting rare cancers and other diseases and to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs; the Company’s belief as to the platform’s capacity to leverage new delivery approaches and/or formulations to enable significant potential enhancements of safety, efficacy and convenience for patients and healthcare providers; the potential of the Company’s portfolio generally, and the potential of RNL™ to safely and effectively deliver a dose of radiation directly to the tumor up to 25 times greater than that currently being given to patients using external beam radiation therapy; the Company’s belief as to the potential of RNL™ to improve brain tumor therapy and that of other difficult to treat radiosensitive tumors; the timing, status, outcome, and anticipated expansion of clinical trials for RNL™, including the planned initiation of an additional Phase 1 study and enrollment at additional sites, and the anticipated timing thereof; the Company’s business expansion outlook for the second half of 2020, including its intended focus on certain additional business expansion milestones; the Company’s expectations regarding the progress and prospect of advancement for the Company, RNL™, and the Company’s portfolio during the second half of 2020; and the potential impact of the COVID-19 pandemic on the Company and its clinical programs, operating results, and financial condition. More information may be found at www.plustherapeutics.com and www.respect-trials.com.Cautionary Statement Regarding Forward-Looking StatementsThis press release contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws.
23, 2020 at 9:09 p.m. Live Call:Phone Number: (877) 402-3914; Conference ID: 5925129 Live Webcast:https://event.on24.com/wcc/r/2402905/A6C80D40192BA72B1FDF935FEAFD7277 Beginning two hours after the conclusion of the conference call, a replay will be available.
Q2 2020 net loss was $1.8 million, or $0.45 per share, including payments to NanoTx LLC of $0.78 million. Have Watchlists?
The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.